Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
NYSE:ABBV's Cash-to-Debt is ranked lower than
88% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NYSE:ABBV: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:ABBV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.62 Max: No Debt
Current: 0.17
Equity-to-Asset 0.07
NYSE:ABBV's Equity-to-Asset is ranked lower than
96% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. NYSE:ABBV: 0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:ABBV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.07 Max: 0.74
Current: 0.07
-0.01
0.74
Interest Coverage 8.96
NYSE:ABBV's Interest Coverage is ranked lower than
73% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.12 vs. NYSE:ABBV: 8.96 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 37.44 Max: No Debt
Current: 8.96
Piotroski F-Score: 6
Altman Z-Score: 2.07
Beneish M-Score: -2.41
WACC vs ROIC
10.71%
21.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 36.60
NYSE:ABBV's Operating Margin % is ranked higher than
96% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. NYSE:ABBV: 36.60 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:ABBV' s Operating Margin % Range Over the Past 10 Years
Min: 17.09  Med: 30.91 Max: 36.6
Current: 36.6
17.09
36.6
Net Margin % 23.22
NYSE:ABBV's Net Margin % is ranked higher than
91% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:ABBV: 23.22 )
Ranked among companies with meaningful Net Margin % only.
NYSE:ABBV' s Net Margin % Range Over the Past 10 Years
Min: 8.89  Med: 22.86 Max: 32.62
Current: 23.22
8.89
32.62
ROE % 117.20
NYSE:ABBV's ROE % is ranked higher than
99% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NYSE:ABBV: 117.20 )
Ranked among companies with meaningful ROE % only.
NYSE:ABBV' s ROE % Range Over the Past 10 Years
Min: 24.85  Med: 91.09 Max: 199.32
Current: 117.2
24.85
199.32
ROA % 9.70
NYSE:ABBV's ROA % is ranked higher than
78% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:ABBV: 9.70 )
Ranked among companies with meaningful ROA % only.
NYSE:ABBV' s ROA % Range Over the Past 10 Years
Min: 6.26  Med: 14.69 Max: 39.54
Current: 9.7
6.26
39.54
ROC (Joel Greenblatt) % 332.23
NYSE:ABBV's ROC (Joel Greenblatt) % is ranked higher than
98% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. NYSE:ABBV: 332.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:ABBV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 75.1  Med: 146.37 Max: 332.23
Current: 332.23
75.1
332.23
3-Year Revenue Growth Rate 10.30
NYSE:ABBV's 3-Year Revenue Growth Rate is ranked higher than
63% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. NYSE:ABBV: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:ABBV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.7 Max: 10.3
Current: 10.3
0
10.3
3-Year EBITDA Growth Rate 15.10
NYSE:ABBV's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. NYSE:ABBV: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:ABBV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 15.1
Current: 15.1
0
15.1
3-Year EPS without NRI Growth Rate 12.30
NYSE:ABBV's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NYSE:ABBV: 12.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:ABBV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.2 Max: 12.3
Current: 12.3
0
12.3
GuruFocus has detected 4 Warning Signs with AbbVie Inc $NYSE:ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ABBV's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Stanley Druckenmiller 1,324,920 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Tom Russo 17,106 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Eaton Vance Worldwide Health Sciences Fund 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Richard Pzena 3,476 sh (New)
Steven Cohen 1,136,566 sh (New)
David Dreman 22,908 sh (+52.53%)
Larry Robbins 9,116,969 sh (+51.19%)
Joel Greenblatt 935,437 sh (+36.69%)
Scott Black 37,816 sh (+2.91%)
Lee Ainslie 50,920 sh (+2.66%)
Manning & Napier Advisors, Inc 160,726 sh (+2.02%)
Ken Fisher 696,569 sh (+1.83%)
Jeff Auxier 20,825 sh (+0.98%)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
NWQ Managers Sold Out
Mario Gabelli 20,076 sh (-0.59%)
Mairs and Power 264,365 sh (-0.78%)
Murray Stahl 33,854 sh (-3.43%)
PRIMECAP Management 901,845 sh (-5.45%)
Stanley Druckenmiller 1,221,723 sh (-7.79%)
Paul Tudor Jones 4,900 sh (-44.94%)
Jim Simons 350,800 sh (-81.71%)
Pioneer Investments 112,829 sh (-90.02%)
Eaton Vance Worldwide Health Sciences Fund 690,536 sh (-7.06%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:OTCPK:GLAXF, OTCPK:BAYRY, NYSE:SNY, NYSE:LLY, NYSE:BMY, NYSE:AZN, NYSE:MRK, NYSE:NVS, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:OPHLY, NYSE:PFE, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, NAS:HCM, OTCPK:BOIRF, NAS:AERI » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the firm's current profits. The company was spun off from Abbott in early 2013.

Top Ranked Articles about AbbVie Inc

Amgen's Humira Biosimilar Approved in Europe The treatment has already been approved in the US
Amgen Inc. (NASDAQ:AMGN) announced in a news release published on its website that Amgevita, the company’s biosimilar to AbbVie Inc.’s (NYSE:ABBV) Humira (adalimumab), has been approved by the European Commission. Read more...
Galapagos Begins Cystis Fibrosis Treatment Study The study will test the treatment's safety, tolerability and pharmacokinetics
Galapagos NV (NASDAQ:GLPG), the Belgian clinical stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for cystic fibrosis, announced March 22 the phase 1 study to assess GLPG3067’s safety, tolerability and pharmacokinetics began. Read more...
AbbVie's Hepatitis C Treatment Under Priority Review in Japan Treatment is supported by multiple studies
AbbVie Inc. (NYSE:ABBV) announced March 14 through the PRNewswire the Japanese Ministry of Health, Labor and Welfare has validated its new drug application for “its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P).” Read more...
Billionaire Investor Is Concentrating on Small-Caps and Pharma Druckenmiller is searching for value in unloved sectors of the market
Stanley Druckenmiller (Trades, Portfolio) is one of the world’s most famous hedge fund managers. His moves are scrutinized by the market for any signs of overly bullish or bearish activity thanks to his history and past performance. Read more...
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study The study compared Xeljanz to Humira
The top-line results from the Oral Strategy trial of Xeljanz were announced Feb. 16 by Pfizer Inc. (NYSE:PFE) through the Business Wire. Read more...
AbbVie Declares Quarterly Dividend Analysts forecast increases in 2017 EPS and sales
AbbVie Inc. (NYSE:ABBV) annouced a quarterly dividend of 64 cents per share on Feb. 16. Read more...
AbbVie's Hepatitis C Treatment Under FDA Review Treatment is supported by multiple studies
AbbVie Inc. (NYSE:ABBV) announced Thursday through the PR Newswire that the U.S. Food & Drug Administration validated its New Drug Application (NDA) for its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).” Read more...
AbbVie to Start Study on Alzheimer's Treatment The treatment is aimed at early-onset Alzheimer's disease
AbbVie Inc. (NYSE:ABBV) announced on Jan. 25 the beginning of two studies to assess 8E12's efficacy and safety in people with early-onset Alzheimer's disease and PSP patients. Read more...
AbbVie Reports 4th-Quarter 2016 Results Company misses revenue, matches earnings
AbbVie Inc. (NYSE:ABBV) closed fourth-quarter 2016 reporting EPS of $1.20, 0.82% lower than third-quarter 2016 EPS of $1.21 and 6.2% higher than fourth-quarter 2015. Read more...
AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Treatment is still waiting for FDA approval
 AbbVie Inc. (NYSE:ABBV) announced Tuesday through the PR Newswire that the European Medicines Agency has validated its marketing authorization application. The company's application seeks permission to rapidly bring its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P)” to the market. Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.15
ABBV's PE Ratio is ranked higher than
74% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.26 vs. ABBV: 18.15 )
Ranked among companies with meaningful PE Ratio only.
ABBV' s PE Ratio Range Over the Past 10 Years
Min: 9.85  Med: 18.67 Max: 63.37
Current: 18.15
9.85
63.37
Forward PE Ratio 12.02
ABBV's Forward PE Ratio is ranked higher than
83% of the 109 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. ABBV: 12.02 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.15
ABBV's PE Ratio without NRI is ranked higher than
73% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.28 vs. ABBV: 18.15 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABBV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.85  Med: 18.67 Max: 63.37
Current: 18.15
9.85
63.37
Price-to-Owner-Earnings 21.16
ABBV's Price-to-Owner-Earnings is ranked higher than
68% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. ABBV: 21.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABBV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.74  Med: 18.36 Max: 61.16
Current: 21.16
13.74
61.16
PB Ratio 23.10
ABBV's PB Ratio is ranked lower than
97% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. ABBV: 23.10 )
Ranked among companies with meaningful PB Ratio only.
ABBV' s PB Ratio Range Over the Past 10 Years
Min: 14.08  Med: 20.27 Max: 76.98
Current: 23.1
14.08
76.98
PS Ratio 4.19
ABBV's PS Ratio is ranked lower than
64% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. ABBV: 4.19 )
Ranked among companies with meaningful PS Ratio only.
ABBV' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 4.19 Max: 5.67
Current: 4.19
2.83
5.67
Price-to-Free-Cash-Flow 16.38
ABBV's Price-to-Free-Cash-Flow is ranked higher than
67% of the 291 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.25 vs. ABBV: 16.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABBV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.66  Med: 14.81 Max: 38.18
Current: 16.38
8.66
38.18
Price-to-Operating-Cash-Flow 15.27
ABBV's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.28 vs. ABBV: 15.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABBV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.2  Med: 13.77 Max: 31.6
Current: 15.27
8.2
31.6
EV-to-EBIT 15.17
ABBV's EV-to-EBIT is ranked higher than
66% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.12 vs. ABBV: 15.17 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.5 Max: 42.5
Current: 15.17
10.2
42.5
EV-to-EBITDA 13.38
ABBV's EV-to-EBITDA is ranked higher than
63% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.99 vs. ABBV: 13.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.6 Max: 34.1
Current: 13.38
8.6
34.1
PEG Ratio 1.92
ABBV's PEG Ratio is ranked lower than
52% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ABBV: 1.92 )
Ranked among companies with meaningful PEG Ratio only.
ABBV' s PEG Ratio Range Over the Past 10 Years
Min: 1.92  Med: 2.34 Max: 2.85
Current: 1.92
1.92
2.85
Current Ratio 1.65
ABBV's Current Ratio is ranked lower than
68% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. ABBV: 1.65 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.65 Max: 2.59
Current: 1.65
1.25
2.59
Quick Ratio 1.51
ABBV's Quick Ratio is ranked lower than
59% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. ABBV: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.51 Max: 2.43
Current: 1.51
1.1
2.43
Days Inventory 104.35
ABBV's Days Inventory is ranked higher than
56% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. ABBV: 104.35 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 89.28 Max: 115.3
Current: 104.35
35.55
115.3
Days Sales Outstanding 67.74
ABBV's Days Sales Outstanding is ranked higher than
58% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. ABBV: 67.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.74  Med: 78.73 Max: 93.3
Current: 67.74
67.74
93.3
Days Payable 88.04
ABBV's Days Payable is ranked higher than
61% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. ABBV: 88.04 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 115.54 Max: 175.86
Current: 88.04
30.33
175.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.57
ABBV's Dividend Yield % is ranked higher than
86% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ABBV: 3.57 )
Ranked among companies with meaningful Dividend Yield % only.
ABBV' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 3.06 Max: 3.96
Current: 3.57
0.85
3.96
Dividend Payout Ratio 0.63
ABBV's Dividend Payout Ratio is ranked higher than
57% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. ABBV: 0.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABBV' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.64 Max: 1.51
Current: 0.63
0.63
1.51
3-Year Dividend Growth Rate 12.50
ABBV's 3-Year Dividend Growth Rate is ranked higher than
58% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. ABBV: 12.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABBV' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.5
Current: 12.5
0
12.5
Forward Dividend Yield % 3.87
ABBV's Forward Dividend Yield % is ranked higher than
88% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABBV: 3.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.54
ABBV's 5-Year Yield-on-Cost % is ranked higher than
72% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. ABBV: 3.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABBV' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 3.05 Max: 3.96
Current: 3.54
0.85
3.96
3-Year Average Share Buyback Ratio -0.80
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. ABBV: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.3 Max: 0
Current: -0.8
-0.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.72
ABBV's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ABBV: 1.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABBV' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.63  Med: 1.63 Max: 1.72
Current: 1.72
1.63
1.72
Price-to-Median-PS-Value 1.00
ABBV's Price-to-Median-PS-Value is ranked higher than
63% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. ABBV: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABBV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.01 Max: 1.26
Current: 1
0.7
1.26
Price-to-Peter-Lynch-Fair-Value 2.84
ABBV's Price-to-Peter-Lynch-Fair-Value is ranked lower than
81% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. ABBV: 2.84 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABBV' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.7  Med: 2.7 Max: 2.85
Current: 2.84
2.7
2.85
Earnings Yield (Greenblatt) % 6.60
ABBV's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. ABBV: 6.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABBV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 6.4 Max: 9.8
Current: 6.6
2.4
9.8
Forward Rate of Return (Yacktman) % 11.62
ABBV's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.75 vs. ABBV: 11.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABBV' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.6  Med: 12.85 Max: 14.5
Current: 11.62
11.6
14.5

More Statistics

Revenue (TTM) (Mil) $25,638
EPS (TTM) $ 3.63
Beta1.47
Short Percentage of Float2.52%
52-Week Range $55.06 - 68.12
Shares Outstanding (Mil)1,593.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27,742 29,890 31,924
EPS ($) 5.38 6.37 7.31
EPS without NRI ($) 5.38 6.37 7.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.73%
Dividends per Share ($) 2.52 2.66 2.77

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)